The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension
Abstract
OBJECTIVE: To determine the best therapeutic strategy for the use of midodrine in patients with neurogenic orthostatic hypotension (NOH). BACKGROUND: Midodrine is a peripherally acting alpha-adrenergic agonist useful in the treatment of NOH. However, neither the most effective dosage of midodrine nor the required frequency of administration is established. DESIGN/METHODS: Midodrine dose-blood pressure response, pharmacokinetics, and duration of action were examined in a double-blind, placebo-controlled, four-way crossover trial. Twenty-five patients with NOH were randomized to receive on successive days placebo or midodrine 2.5, 10, or 20 mg. Blood pressures of patients in the supine and standing positions were measured sequentially. A global assessment of the patient's overall symptom improvement after each leg of the study was performed. Blood levels of midodrine and its active metabolite, desglymidodrine, were assayed. RESULTS: Midodrine significantly increased standing systolic blood pressure, with the increase peaking at 1 hour. There was a significant linear relation between midodrine dosage and mean systolic blood pressure. The mean score for global improvement of symptoms was significantly higher for midodrine (10 and 20 mg) compared with placebo. The half-life of desglymidodrine was approximately 4 hours. CONCLUSION: A 10-mg dose of midodrine prescribed two to three times daily is effective in increasing orthostatic blood pressure and ameliorating symptoms in patients with NOH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is no doubt that midodrine increases BP both in the supine and upright posture, and ameliorates the symptoms of OH.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [326]
In the citing paper
“Midodrine (2.5-10 mg t.i.d) was shown to be effective in three randomized placebo-controlled trials. 324-326”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [326]
Citations
Cites
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine
Jankovic, J., Gilden, J. L., Hiner, B. C., Kaufmann, H., Brown, D. C., Coghlan, C. H., Rubin, M., & Fouad-Tarazi, F. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90230-m · Cited by 396
Self-citationMcTavish, D., & Goa, K. L. (1989) · Drugs · doi:10.2165/00003495-198938050-00004 · Cited by 160
Kaufmann, H., Brannan, T. S., Krakoff, L. R., Yahr, M. D., & Mandeli, J. (1988) · Neurology · doi:10.1212/wnl.38.6.951 · Cited by 136
Self-citationPharmacodynamics of midodrine, an antihypotensive agent
Zachariah, P. K., Bloedow, D. C., Moyer, T. P., Sheps, S. G., SCHIRGER, A., & Fealey, R. D. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.101 · Cited by 57
[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride].
Grobecker, H., Kees, F., Linden, M., Schrader, E., & Welte, S. (1987) · PubMed · Cited by 10
Research works printed but not linked: 5
- Thomas JE, Schirger A. Idiopathic orthostatic hypotension. A study of its natural history in 57 neurologically affected persons. Arch Neurol 1970;22:289-293.
- Cohen J, Low P, Fealey R, Sheps S, Jiang N-S. Somatic and autonomic function in progressive autonomic failure and multiple system atrophy. Ann Neurol 1987;22:692-699.
- Thulesius O, Gjores JE, Berlin E. Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins. Eur J Clin Pharmacol 1979;16:423-424.
- Schatz IJ. Orthostatic hypotension: II. Clinical diagnosis, testing and treatment. Arch Intern Med 1984;144:1037-1041.
- Pittner H, Stormann H, Enzenhofer R. Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059. Arzneimittelforschung 1976;26:2145-2154.
Cited by
Sorted by citations
Items 301–330 of 330
Synkopenmanagement in der Praxis: Was ändert sich gemäß den neuen ESC-Leitlinien 2018?
Oebel, S., & Hindricks, G. (2018) · Herz
Orthostatische Hypotension: Diagnostik und Therapie
Schimpf, R., Veltmann, C., & Borggrefe, M. (2011) · Herzschrittmachertherapie + Elektrophysiologie
Pérez‐Soriano, A. (2021) · Kranion · doi:10.24875/kranion.m21000005
Yang, S., & ZIMETBAUM, P. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-88953-1_4
Autonomic dysfunction and management
Dewey, R. B., Khemani, P., Karunapuzha, C. A., & Chitnis, S. (2013) · Informa Healthcare eBooks · doi:10.3109/9781841849096.006
Bianco, C. M., Nekkanti, R., Latif, F., Hung, P. N., Tran, P., An, H. T., & Nguyen, T. N. (2016) · Wiley eBooks · doi:10.1002/9781118965061.ch10
Gómez, J. J. G., Hernández, A. H., & Zapater, E. L.-Z. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70619-x
Haustein, K.-O. (2000) · Springer eBooks · doi:10.1007/978-3-642-57215-9_13
Pharmacokinetics and Pharmacotherapeutics in Spinal Cord Injuries
Ko, H.-Y. (2022) · Springer eBooks · doi:10.1007/978-981-19-0228-4_10
Hypotension orthostatique : attention à la chute
Michon, P.-L., Grognet, A., Cudennec, T., & Pépin, M. (2023) · Soins Gérontologie · doi:10.1016/j.sger.2023.01.008
Understanding Pharmacokinetics and Pharmacotherapeutics in the Management of Spinal Cord Injuries
Ko, H.-Y. (2023) · Springer eBooks · doi:10.1007/978-981-99-4542-9_8
Talati, A., Karalasingham, K., Lei, L. Y., Sheldon, R. S., & Raj, S. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00026-1
Mahmoud, M. A., Osman, H. A. M., & Hamed, K. A. E. (2025) · Anaesthesia Pain & Intensive Care · doi:10.35975/apic.v29i3.2752
Diagnóstico y tratamiento de la hipotensión ortostática neurogénica
López-Bravo, A. (2025) · Kranion · doi:10.24875/kranion.m25000103
Approaches for treating cardiovascular symptoms in Parkinson’s disease
Jost, W. H., & Koschel, J. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251375181
Parasympathetic and Sympathetic Nervous System Dysfunction and Monitoring
DePace, N. L., Soloway, S., Yayac, M. F., & Colombo, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-88769-7_13
Treatment of Dementia with Lewy Bodies
Boeve, B. F. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.023
Tremblay, J.-A., Laramée, P., Lamarche, Y., Denault, A. Y., Beaubien‐Souligny, W., Frenette, A.-J., Kontar, L., Serri, K., & Charbonney, E. (2020) · Figshare · doi:10.6084/m9.figshare.12955873
Tremblay, J.-A., Laramée, P., Lamarche, Y., Denault, A. Y., Beaubien‐Souligny, W., Frenette, A.-J., Kontar, L., Serri, K., & Charbonney, E. (2020) · Figshare · doi:10.6084/m9.figshare.12955876
Tremblay, J.-A., Laramée, P., Lamarche, Y., Denault, A. Y., Beaubien‐Souligny, W., Frenette, A.-J., Kontar, L., Serri, K., & Charbonney, E. (2020) · Figshare · doi:10.6084/m9.figshare.12955870
Doyle, K., Rice, C. P., Kenny, R. A., Briggs, R., & Lavan, A. H. (2026) · Blood Pressure · doi:10.1080/08037051.2026.2618319
Writers, A. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0103-3
Gibson, G. A., Lista, A. D., & Pouliot, J. D. (2026) · Journal of Pharmacy Practice · doi:10.1177/08971900261431490
Rajesh, S., Lee, G. R., Gao, K. J., Verma, A., & Juraschek, S. P. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01368-5
Orthostatic hypotension: new frontiers in pharmacotherapeutic management
Baker, J. R., & Raj, S. R. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2688305
Skarin, M., Collier, J., Rice, D., McNair, P., & Kluger, M. T. (2026) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2026.112261
Management of fragile X-associated tremor ataxia syndrome: a review for clinicians
Hall, D. A., González, D. A., Klusek, J., Todd, P. K., O’Keefe, J. A., Maltman, N., Montanaro, F. A. M., Protic, D. D., Scorr, L., Malik, R., et al. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1870779
Midodrine as a Countermeasure to Orthostatic Hypotension Immediately After Space Shuttle Landing
Platts, S. H., Stenger, M. B., Ribeiro, L. C., & Lee, S. M. C. (2010) · NASA Technical Reports Server (NASA)
Hypotension orthostatique : mécanismes, étiologies et principes de traitement
Blétry, O., & Marroun, I. (2013) · Time to knit · doi:10.1016/s1634-6939(13)59290-8
Metadata
- Authors
- Wright, R. A., Kaufmann, H. C., Perera, R., Opfer-Gehrking, T. L., McElligott, M. A., Sheng, K. N., & Low, P. A.
- Affiliations
- Mayo Clinic (US)
- Venue
- Neurology
- Published
- 1998-07
- Volume
- 51
- Issue
- 1
- Pages
- 120-124
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2048764982
- Cited by
- 331
- References
- 5
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 8 · 2023: 11 · 2022: 12 · 2021: 14 · 2020: 23 · 2019: 8 · 2018: 16 · 2017: 24 · 2016: 9 · 2015: 16 · 2014: 24 · 2013: 22 · 2012: 5
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Foundation for Medical Education and Research
- National Institutes of Health (1p01ns032352-01a1)
- National Institute of Neurological Disorders and Stroke (P01 NS 32352)
- National Center for Research Resources (5MO RR00071)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Syncope and Autonomic Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- midodrine, neurogenic orthostatic hypotension, alpha-adrenergic agonists, dose-response relationship, pharmacokinetics, blood pressure, symptom improvement
- MeSH terms
- Adrenergic alpha-Agonists, Adult, Aged, Autonomic Nervous System Diseases, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hypotension, Orthostatic, Male, Middle Aged, Midodrine, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
